• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC NEUROMODULATION IMPLANTABLE NEUROSTIMULATOR; STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC NEUROMODULATION IMPLANTABLE NEUROSTIMULATOR; STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS Back to Search Results
Model Number NEU_INS_STIMULATOR
Device Problems Adverse Event Without Identified Device or Use Problem (2993); Insufficient Information (3190)
Patient Problem Suicidal Ideation (4429)
Event Date 12/28/2023
Event Type  Injury  
Manufacturer Narrative
A: select patient information cannot be included in regulatory report due to regional privacy regulations.B.3.Please note that this date is based off of the date of publication of the article as the event dates were not provided in the published literature.D10.Section d information references the main component of the system.Other relevant device(s) are: product id: 3387, serial/lot #: unknown, https://www.Brainstimjrnl.Com/article/s1935-861x(23)01979-4/fulltext.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Persad ar, coote nr, waterhouse k, et al.Medial forebrain bundle stimulation after failed subcallosal cingulate deep brain stimulation for treatment-resistant depression: efficacy of a dual deep brain stimulation system for depression.Brain stimul.2023;17(1):68-70.Doi: 10.1016/j.Brs.2023.12.014.Reported events: two patients had subcallosal cingulate cortex (scc) dbs performed without sustained symptom relief who then had medial forebrain bundle (mfb) dbs and had improved symptom relief with both systems activated.In both cases, the effects of having both systems exceed the effect of either system individually.  1.One patient had 15 year history of depression.The patient received scc unit 5 years prior due to recurrent suicidal ideation.They had electroconvulsive therapy with minimal results.Following scc dbs, they initially felt mild improvement but this was transient.Three years following scc dbs, the patient was admitted to hospital with a suicide attempt.Their psychiatrist recommended mfb dbs due to inadequate response to scc dbs. the patient reported subjective improvement at 1-week follow-up.Their scc dbs started off, but was turned on at 5-month follow-up.They had further clinical improvement with both systems on.The patient's family immediately noticed change after mfb dbs battery stopped working at 18 months follow-up, but took longer to notice differences after the scc dbs battery failed.The patient had no suicide or self-harm attempts since mfb dbs.They were able to stop aripiprazole on dual stimulation.The following device specifics was provided: lead model 3387.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMPLANTABLE NEUROSTIMULATOR
Type of Device
STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS
Manufacturer (Section D)
MEDTRONIC NEUROMODULATION
7000 central ave ne
minneapolis MN 55432
Manufacturer (Section G)
MEDTRONIC NEUROMODULATION
7000 central ave ne
minneapolis MN 55432
Manufacturer Contact
glen belmer
7000 central avenue ne rcw215
minneapolis, MN 55432
6122713209
MDR Report Key18731182
MDR Text Key335691375
Report Number2182207-2024-00780
Device Sequence Number1
Product Code MHY
Combination Product (y/n)N
Reporter Country CodeCA
PMA/PMN Number
P960009
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Physician
Type of Report Initial
Report Date 02/19/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/19/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberNEU_INS_STIMULATOR
Device Catalogue NumberNEU_INS_STIMULATOR
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/22/2024
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
"SEE H11...."
Patient Outcome(s) Hospitalization; Life Threatening;
-
-